Published online 22 June 2009
Haematologica, Vol 94, Issue 8, 1179-1181 doi:10.3324/haematol.2009.006346
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kristinsson, S. Y.
Right arrow Articles by Landgren, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kristinsson, S. Y.
Right arrow Articles by Landgren, O.

Monoclonal Gammopathies

Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance

Sigurdur Y. Kristinsson1, Lynn R. Goldin2, Magnus Björkholm1, Ingemar Turesson3, Ola Landgren1,2

1 Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden;
2 National Cancer Institute, National Institutes of Health, Bethesda, Md, USA;
3 Department of Medicine, Section of Hematology, Malmö University Hospital, Malmö, Sweden

Correspondence: Sigurdur Yngvi Kristinsson, M.D., Department of Medicine Division of Hematology, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden. Phone: international +46.8.51770000; Fax: international +46.8.318264. E-mail:sigurdur.kristinsson{at}karolinska.se

Key words: MGUS, solid tumors, familial aggregation, susceptibility.

Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common pre-malignant disorders in western countries with a prevalence of 3.2% in the Caucasian general population 50 years of age or older.1 It is characterized by the presence of a monoclonal immunoglobulin (M-protein) in individuals lacking evidence of multiple myeloma (MM) or other lymphoproliferative malignancies.2 Long-term follow-up of MGUS patients reveals an average 1% annual risk of developing a lymphoproliferative malignancy.3,4 Although the etiology of MM and MGUS is unknown, there is emerging evidence to support a role for genetic factors. For example, familial aggregation of both MM and MGUS has been observed.5 Also racial disparities in incidence patterns for MGUS and MM support a role for germline genes in the etiology of MM.6 Recently, we found first-degree relatives of MGUS patients to have an increased risk of MGUS, MM, lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia, supporting a role for shared common germline susceptibility genes in these disorders.5 Furthermore, in two recent studies an excess of certain solid tumors among blood relatives to MM patients was reported.7,8

To improve our understanding in this area, we have, to the best of our knowledge, conducted the first population-based study to evaluate familial aggregation patterns of 27 solid tumors and all myeloid hematologic malignancies among first-degree blood relatives of MGUS patients. Using high-quality population-based data from Sweden, we identified 4,458 MGUS patients and 17,505 controls, as well as all linkable first-degree relatives of patients (n=14,621) and controls (n=58,387) (Table 1). We used {chi}2 models to calculate relative risks (RR) and 95% confidence intervals (CI) as measures of familial aggregation.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		Table 1. Characteristics of MGUS patients and matched controls.

Compared to relatives of controls, first-degree relatives of MGUS patients had a borderline increased risk of any solid tumor (RR=1.1; 95% CI 1.04–1.21; p=0.004). When we assessed individual tumor sites, we found evidence of a significantly increased risk for bladder cancer (RR=1.4; 95% CI 1.02–1.84; p=0.035) and, based on small numbers, a 3.0-fold (95% CI 1.04–8.64; p=0.033) increased risk for spinal cancer. We also found borderline increased risks for malignant melanoma (RR=1.3; 95% CI 1.00–1.62; p=0.051) and lung cancer (RR=1.2; 95% CI 0.98–1.58; p=0.078). No significantly increased risk was found for any of the other solid tumor sites (Table 1). Neither did we find relatives of MGUS patients to have a significantly increased risk for myeloid hematologic malignancies (Table 1). In analyses stratified by MGUS isotype, the risks were essentially the same (data not shown).

The observed increased risk for bladder cancer among relatives of MGUS patients agrees with a prior study showing evidence of co-aggregation of MM and bladder cancer.9 Furthermore, in a study based on patients with a coexisting MGUS and a solid tumor, 24% had bladder cancer.10 Also in agreement with a previous study by Camp et al.,7 we found first-degree relatives of MGUS cases to have a borderline increased risk of malignant melanoma. These findings are further supported by a prior genotyping study, suggesting that germline mutations in the CDKN2A gene may predispose to both MM and malignant melanoma.11 Our finding of a borderline increased risk of lung cancer among relatives of MGUS patients needs to be confirmed by other studies. However, one small study found family history of lung cancer to be associated with an increased risk of MM in elderly patients,12 a finding not observed in our previous Swedish MM study.6 In contrast to two prior studies focusing on solid cancers in MM families, 7,8 we did not find a significantly increased risk of prostate cancer among MGUS relatives. Based on small numbers, we found excess risk of spinal cancer among MGUS relatives. Because we evaluated a large number of malignancies, it cannot be ruled out that this finding is due to chance. Finally, we did not find an increased risk of myeloid malignancies among first-degree relatives suggesting that myeloid and lymphoid hematologic malignancies have different mechanisms with regard to etiology. Our study has several strengths, including its large size as well as the application of high-quality data. The use of the nationwide register-based case-control design ruled out recall-bias, ensured a population-based setting, and generalizability of our findings. The nature of this study is hypothesis-generating and one has to interpret our findings with caution due to the large number of tested malignancies.

Our findings support a role for a shared susceptibility (genetic, environmental, or both) that predisposes to MGUS and certain solid tumors, supporting the application of gene mapping and candidate gene approaches in high-risk families and case-control studies.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		Table 2. Relative risk of solid tumors and hematologic myeloid malignancies among first-degree relatives of MGUS patients.


arrow
Acknowledgments
 
the authors thank Ms. Shiva Ayobi, The National Board of Health and Welfare, Stockholm, Sweden; Ms. Susanne Dahllöf, Statistics Sweden, Orebro, Sweden; Ms. Charlotta Ekstrand, Ms. Molly Collin and Ms. Lisa Camner, Karolinska Institutet, Stockholm, Sweden, for invaluable ascertainment of MGUS data; and Ms. Emily Steplowski, Information Management Services, Silver Spring, MD, for important efforts in the development of this database. The authors have no conflict of interest to declare.


arrow
Footnotes
 
Funding: This research was supported by grants from the Swedish Cancer Society, Stockholm County Council, the Karolinska Institutet Foundations, and the Intramural Research Program of the NIH, NCI.


arrow
References
TOP
 References
 
  1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.[Abstract/Free Full Text]
  2. Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.[CrossRef][Web of Science][Medline]
  3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.[Abstract/Free Full Text]
  4. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759-64.[Abstract/Free Full Text]
  5. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et al. Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden. Blood 2009;[Epub ahead of print].
  6. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8.[CrossRef][Web of Science][Medline]
  7. Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. N Engl J Med 2008;359:1734-5.[Free Full Text]
  8. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med 2008;359:152-7.[Abstract/Free Full Text]
  9. Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001;166:2129-33.[CrossRef][Web of Science][Medline]
  10. Anagnostopoulos A, Galani E, Gika D, Sotou D, Evangelopoulou A, Dimopoulos MA. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Ann Hematol 2004;83:658-60.[Web of Science][Medline]
  11. Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 2000;95:1869-71.[Abstract/Free Full Text]
  12. Bourguet CC, Grufferman S, Delzell E, DeLong ER, Cohen HJ. Multiple myeloma and family history of cancer. A case-control study. Cancer 1985;56:2133-9.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 haematolHome page
S. Y. Kristinsson, L. R. Goldin, M. Bjorkholm, J. Koshiol, I. Turesson, and O. Landgren
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
Haematologica, November 1, 2009; 94(11): 1581 - 1589.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kristinsson, S. Y.
Right arrow Articles by Landgren, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kristinsson, S. Y.
Right arrow Articles by Landgren, O.